Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries.

Greenberg B, Rhoden K, Barnes PJ

Blood vessels1 Jan 1987Cited by 34 (Europe PMC)

PMID3567364DOI10.1159/000158670PepBankPUB-03567364

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In isolated bovine and human intrapulmonary artery segments, VIP caused nearly complete relaxation of precontracted vessels.
In plain wordsIn lab tests on cow and human lung artery tissue, VIP relaxed the vessel segments almost completely.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseRelaxation of precontracted pulmonary artery
Study
bovine and humann: not reported in source
isolated precontracted intrapulmonary artery segments
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In both species, VIP caused nearly complete relaxation of precontracted vessel segments.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the functional effects of vasoactive intestinal peptide (VIP) and the structurally related peptide histidine isoleucine (PHI) in segments of bovine and human intrapulmonary artery.
Report a problemFND-0356736401
02LabEx vivo tissueActivity measurement
In bovine intrapulmonary artery segments, the EC50 of VIP for relaxation was in the nanomolar range.
In plain wordsIn lab tests on cow lung artery tissue, VIP relaxed the vessel at very low nanomolar concentrations.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP EC50 in bovine pulmonary artery
Study
bovinen: not reported in source
isolated precontracted intrapulmonary artery segments
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Measurements
EC50
1.3 10(-9) M
bovine pulmonary artery
Source sentences
Summary
The EC50 was 1.3 +/- 0.3 X 10(-9) M (mean +/- SD) in bovine and 3.4 +/- 0.4 X 10(-9) M in human pulmonary artery.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the functional effects of vasoactive intestinal peptide (VIP) and the structurally related peptide histidine isoleucine (PHI) in segments of bovine and human intrapulmonary artery.
Report a problemFND-0356736402
03LabEx vivo tissueActivity measurement
In human intrapulmonary artery segments, the EC50 of VIP for relaxation was in the nanomolar range.
In plain wordsIn lab tests on human lung artery tissue, VIP relaxed the vessel at very low nanomolar concentrations.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP EC50 in human pulmonary artery
Study
humann: not reported in source
isolated precontracted intrapulmonary artery segments
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Measurements
EC50
3.4 10(-9) M
human pulmonary artery
Source sentences
Summary
The EC50 was 1.3 +/- 0.3 X 10(-9) M (mean +/- SD) in bovine and 3.4 +/- 0.4 X 10(-9) M in human pulmonary artery.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the functional effects of vasoactive intestinal peptide (VIP) and the structurally related peptide histidine isoleucine (PHI) in segments of bovine and human intrapulmonary artery.
Report a problemFND-0356736403
04LabEx vivo tissueMechanism
In bovine and human pulmonary artery segments, the VIP response did not depend on endothelium and was not changed by adrenergic or cholinergic blockade or by cyclooxygenase inhibition.
In plain wordsIn lab tests on lung artery tissue, VIP relaxation did not need the vessel lining and was not changed by the blockers tested.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeDependence of VIP relaxation on endothelium, blockers and cyclooxygenase
Study
bovine and humann: not reported in source
isolated precontracted intrapulmonary artery segments
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The response to VIP was not endothelium-dependent and it was not affected by either adrenergic and cholinergic blockade or by cyclooxygenase inhibition.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the functional effects of vasoactive intestinal peptide (VIP) and the structurally related peptide histidine isoleucine (PHI) in segments of bovine and human intrapulmonary artery.
Report a problemFND-0356736404
05LabEx vivo tissueEfficacy outcome
In bovine and human pulmonary arteries, VIP relaxed vessels more effectively than PHI.
In plain wordsIn lab tests on cow and human lung artery tissue, VIP relaxed the vessels more than the related peptide PHI.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseRelaxation by VIP compared with PHI
Study
bovine and humann: not reported in source
isolated precontracted intrapulmonary artery segments
Comparator
PHI
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
PHI also relaxed human and bovine vessels but this related peptide was significantly less effective than VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the functional effects of vasoactive intestinal peptide (VIP) and the structurally related peptide histidine isoleucine (PHI) in segments of bovine and human intrapulmonary artery.
Report a problemFND-0356736405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.